News from Symphogen

Jan 14, 2014, 13:30 ET

Symphogen Presents Corporate Progress and Outlook at JP Morgan's 32nd Annual Healthcare Conference in San Francisco, CA

Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today presented its...

Dec 20, 2013, 04:01 ET

Symphogen Announces the Appointment of Annika Espander Jansson as Non-Executive Director

Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today announces the...

May 02, 2013, 07:33 ET

Symphogen Expands Previous Private Equity Round, Reaching a Total of € 141 Million (USD 185 Million)

Symphogen will host a conference call today (2 May 2013) to discuss the announcement at 13:00 CET / 12:00 BST; details on how access this call and...

Sep 06, 2012, 01:46 ET

Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA

- Symphogen Will Host a Conference Call Today (Thursday 6 September 2012) to Discuss the Announcement at 11:30 CET/ 10:30 BST, Details on How...

Jun 03, 2004, 01:00 ET

Symphogen A/S Appoints Laurence Jay Korn to its Board of Directors

COPENHAGEN, Denmark, June 3 /PRNewswire/ -- The Danish biotech company Symphogen A/S today announced the appointment of Dr. Laurence Jay Korn,...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
ReportBuyer
Analysts Review